SVRA compared with GLUE: revenue, margins and what each company keeps, and the suppliers and customers both name

SVRASavara Inc

Mkt capRevenueRevenue

GLUEMonte Rosa Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

SVRASavara Inc

GLUEMonte Rosa Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SVRA

No earnings history for SVRA.

GLUE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±21.6%▼−5.27%×0.25

Q2 FY26±15.6%▲+0.64%×0.04

May 7 '26±25.6%▼−2.84%×0.11

Q1 FY26±24.5%▼−1.96%×0.08

= impliedSVRA realized, solidGLUE realized, hatchedOne scale, both sides: full bar = 26%× = |realized| ÷ impliedSource: market data

SVRASavara Inc

4.83▲+10.27%· post 4.84

Mkt cap$992.4MRevenue—Revenue—

GLUEMonte Rosa Therapeutics, Inc.

10.57▲+3.09%· post 10.57

ClosedNov 6 '26

Mkt cap$903.2MRevenue$54MQ3 FY26Revenue$124MFY25

Compare

ClosedNov 6 '26

SVRASavara Inc

GLUEMonte Rosa Therapeutics, Inc.

4.83▲+10.27%post 4.84

Price

10.57▲+3.09%post 10.57

$992.4M

Mkt cap

$903.2M

—

Revenue

$54MQ3 FY26

—

Revenue

$124MFY25

SVRA4.83▲+10.27%vsGLUE10.57▲+3.09%ClosedNov 6 '26